TAGAMET Drug Patent Profile

✉ Email this page to a colleague

When do Tagamet patents expire, and what generic alternatives are available?

Tagamet is a drug marketed by Glaxosmithkline and Medtech Products and is included in six NDAs.

The generic ingredient in TAGAMET is cimetidine. There are twenty-five drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cimetidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tagamet

A generic version of TAGAMET was approved as cimetidine by MYLAN on May 17^th, 1994.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TAGAMET?
What are the global sales for TAGAMET?
What is Average Wholesale Price for TAGAMET?

Summary for TAGAMET

US Patents:	0
Applicants:	2
NDAs:	6
Raw Ingredient (Bulk) Api Vendors:	178
Clinical Trials:	7
Patent Applications:	6,461
Drug Prices:	Drug price information for TAGAMET
What excipients (inactive ingredients) are in TAGAMET?	TAGAMET excipients list
DailyMed Link:	TAGAMET at DailyMed

Drug patent expirations by year for TAGAMET

Recent Clinical Trials for TAGAMET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 4
University of Washington	Phase 4
National Institutes of Health (NIH)	Early Phase 1

See all TAGAMET clinical trials

US Patents and Regulatory Information for TAGAMET

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	TAGAMET	cimetidine hydrochloride	INJECTABLE;INJECTION	017939-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Medtech Products	TAGAMET HB	cimetidine	TABLET;ORAL	020238-001	Jun 19, 1995		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Glaxosmithkline	TAGAMET	cimetidine	TABLET;ORAL	017920-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for TAGAMET

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	TAGAMET	cimetidine	TABLET;ORAL	017920-003	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Glaxosmithkline	TAGAMET	cimetidine hydrochloride	INJECTABLE;INJECTION	017939-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Glaxosmithkline	TAGAMET	cimetidine hydrochloride	SOLUTION;ORAL	017924-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for TAGAMET

See the table below for patents covering TAGAMET around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
United Kingdom	1395929		⤷ Sign Up
Israel	38821	HETEROCYCLIC DERIVATIVES OF UREA,THIOUREA AND GUANIDINE	⤷ Sign Up
Japan	S579765	MANUFACTURE OF HETEROCYCLIC COMPOUND	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for TAGAMET

Recent Clinical Trials for TAGAMET

Make Better Decisions: Try a trial or see plans & pricing